Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

A 6-Month Open Pilot Study to Investigate the Safety and Tolerability of Immediate Conversion From Calcineurin Inhibitor Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

The purpose of this study is to investigate safety and tolerability of an immediate conversion from Tacrolimus to everolimus in stable renal allograft recipients.

Interest in developing CNI-free regimens using other agents such as the proliferation signal inhibitor everolimus.

Inclusion criteria

• Primary or secondary renal transplantation in the past 12-36 months.
• Current immunosuppressive therapy consisting of Tacrolimus together with MMF +/-corticosteroids.
• Moderately impaired renal function

Exclusion criteria

• Multi-organ recipients or previous transplantation with an organ other than a kidney.
• Acute rejection episodes in the last 6 months.

Other protocol-defined inclusion/exclusion criteria may apply.